Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
Mohamed AttauabiCamilla HöglundJanne FassovKenneth Bo PedersenHeidi Bansholm HansenSigne WildtMichael Dam JensenAnders NeumannCecilie LindHenrik Albaek JacobsenAna-Maria PopaJens KjeldsenNatalia PedersenAkbar MolazahiKent HaderslevClaus AalykkeTorben KnudsenWojciech CebulaPia MunkholmFlemming BendtsenJakob Benedict SeidelinBurisch JPublished in: Scandinavian journal of gastroenterology (2021)
Vedolizumab is effective in the achievement of short-term, long-term, and steroid-free clinical remission in bio-naïve UC and CD patients.